The trial was conducted at 29 sites in the United States, Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Poland, Singapore, Spain, and the United Kingdom.The major efficacy outcome measure was progression-free survival (PFS) based on assessment by blinded independent central review (BICR) using modified RECIST 1.1 in which lymph nodes and bone lesions were not target lesions and a progressively growing new tumor nodule within a pre-existing tumor mass must meet specific criteria to be considered unequivocal evidence of progression. Additional efficacy outcome measures included overall response rate (ORR) by BICR and overall survival (OS). The trial demonstrated a statistically significant improvement in PFS for participants in the ripretinib arm compared with those in the placebo arm (HR 0.15; 95% CI: 0.09, 0.25; p<0.0001).The U.S. Food and Drug Administration (FDA) granted the application for ripretinib priority review and fast track designations, as well as breakthrough therapy designation and orphan drug designation. The FDA granted approval of Qinlock to Deciphera Pharmaceuticals, Inc.

Society and culture
Legal status
Ripretinib was approved for medical use in the United States in May 2020, and in Australia in July 2020.On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Qinlock, intended for the treatment of advanced gastrointestinal stromal tumour (GIST) in people who have received prior treatment with three or more kinase inhibitors.
The applicant for this medicinal product is Deciphera Pharmaceuticals (Netherlands) B.V. Ripretinib was approved for medical use in the European Union in November 2021. Names
Ripretinib is the International nonproprietary name (INN) and the United States Adopted Name (USAN). References
Further reading
Schneeweiss M, Peter B, Bibi S,  et al. (May 2018). "The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis". Haematologica. 103 (5): 799–809. doi:10.3324/haematol.2017.179895. PMC 5927976. PMID 29439183. External links
"Ripretinib". Drug Information Portal. U.S. National Library of Medicine. "Ripretinib". NCI Drug Dictionary. National Cancer Institute. "Ripretinib". National Cancer Institute. 27 May 2020. Clinical trial number NCT03353753 for "Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)" at ClinicalTrials.gov